SCHEMBL28931959

SCHEMBL28931959

O=C(Nc1ncc(-c2ccc(Cl)cc2)[nH]1)c1cc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 1/20 0.59
▸ CYP3A4 P08684 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.56
▸ LMNA P02545 5/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ HTT P42858 3/20 0.55
▸ TACR3 P29371 1/20 0.54
▸ HPGD P15428 4/20 0.53
▸ MCL1 Q07820 1/20 0.53
▸ KMT2A Q03164 7/20 0.53
▸ MEN1 O00255 6/20 0.53
▸ GFER P55789 1/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ USP2 O75604 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ MAPT P10636 5/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ HSP90AA1 P07900 1/20 0.52
▸ AGTR1 P30556 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28699068 0.88 STAT3 (0.54) STAT3ALDH1A1LMNAKDM4EHTT
SCHEMBL28691066 0.87 CYP3A4 (0.68) CYP3A4ALDH1A1LMNAKDM4EHTT
SCHEMBL28699070 0.86 MAPT (0.57) CYP3A4ALDH1A1LMNAKDM4EHPGD
SCHEMBL28672666 0.86 CYP2C9 (0.68) CYP3A4ALDH1A1LMNAKDM4EHPGD
SCHEMBL28680454 0.84 TP53 (0.55) CYP3A4ALDH1A1LMNAKDM4EHTT
SCHEMBL28690150 0.84 STAT3 (0.61) STAT3CYP3A4LMNAKDM4EHTT
SCHEMBL28681436 0.82 STAT3 (0.61) STAT3CYP3A4ALDH1A1LMNAKDM4E
SCHEMBL28690124 0.81 ALDH1A1 (0.58) STAT3ALDH1A1LMNAKDM4EHTT
SCHEMBL28695985 0.79 STAT3 (0.55) STAT3CYP3A4ALDH1A1LMNAKDM4E
SCHEMBL19501569 0.78 NPC1 (0.52) KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113747920-A Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivatives 株式会社益力多本社 2021-12-03 — — CN disclosed
CN-112703001-A Combination cancer therapy using quinoline carboxamide derivatives 株式会社益力多本社 2021-04-23 — — CN disclosed
Send feedback